Table 6.
Level | Response | Remission | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
N (%) | Odds Ratio | LowerCL | UpperCL | p-value | N (%) | Odds Ratio | LowerCL | UpperCL | p-value | |
Age | ||||||||||
age 18–34 (referent) | 357 (42.1) | – | – | – | – | 166 (19.6) | – | – | – | – |
age 35–54 | 328 (45.4) | 0.9 | 0.7 | 1.2 | 0.600 | 153 (21.2) | 0.9 | 0.7 | 1.2 | 0.560 |
age 55–74 | 210 (54.0) | 1.3 | 0.9 | 1.7 | 0.176 | 108 (27.8) | 1.3 | 0.9 | 1.8 | 0.182 |
age > =75 | 13 (81.3) | 1.8 | 0.4 | 7.8 | 0.453 | 8 (50.0) | 1.7 | 0.5 | 5.4 | 0.363 |
Race | ||||||||||
White (referent) | 660 (44.8) | – | – | – | – | 311 (21.1) | – | – | – | – |
AI/AN | 182 (52.8) | 1.2 | 0.7 | 1.8 | 0.523 | 87 (25.2) | 0.9 | 0.6 | 1.4 | 0.654 |
Other | 71 (40.6) | 0.9 | 0.6 | 1.3 | 0.485 | 38 (21.7) | 1.4 | 0.9 | 2.2 | 0.177 |
Gender | ||||||||||
Male (referent) | 307 (44.3) | – | – | – | – | 135 (19.5) | – | – | – | – |
Female | 600 (46.7) | 1.1 | 0.8 | 1.4 | 0.605 | 299 (23.3) | 1.3 | 1.0 | 1.8 | 0.036 |
Site | ||||||||||
Clinic C (referent) | 294 (19.3) | – | – | – | – | 638 (41.9) | – | – | – | – |
Clinic F | 72 (34.8) | 3.4 | 2.1 | 5.5 | < 0.001 | 137 (66.2) | 2.2 | 1.5 | 3.4 | < 0.001 |
Clinic G | 70 (26.7) | 0.9 | 0.6 | 1.5 | 0.779 | 138 (52.7) | 1.0 | 0.6 | 1.7 | 0.922 |
Severity of Max PHQ | ||||||||||
continuous | – | 0.8 | 0.8 | 0.8 | < 0.001 | – | 0.8 | 0.8 | 0.9 | < 0.001 |
Treatment Duration (months) | ||||||||||
continuous | – | 1.1 | 1.1 | 1.2 | < 0.001 | – | 1.1 | 1.0 | 1.1 | 0.009 |
Total Treatment Episodes | ||||||||||
1 episode (referent) | 795 (47.5) | – | – | – | – | 382 (22.8) | – | – | – | – |
two or more episodes | 118 (37.0) | 0.5 | 0.4 | 0.8 | < 0.001 | 54 (16.9) | 0.7 | 0.5 | 1.0 | 0.035 |
Total FU | ||||||||||
< =1 FU (referent) | 95 (32.4) | – | – | – | – | 40 (13.7) | – | – | – | – |
2–3 FU | 208 (45.5) | 2.4 | 1.7 | 3.5 | < 0.001 | 87 (19.0) | 1.8 | 1.1 | 2.8 | 0.011 |
4–7 FU | 268 (62.0) | 4.9 | 3.3 | 7.3 | < 0.001 | 149 (34.5) | 4.4 | 2.8 | 7.0 | < 0.001 |
Initial predictors entered prior to variable selection: age, race, gender, treatment duration (months), number of episodes, number of follow-ups, first follow-up within 31 days, at least one psychiatric consultation note